MUNICH & GARCHING, Germany--(BUSINESS WIRE)--Oct 7, 2019--

ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, announced today that ITM´s subsidiary, ITG Isotope Technologies Garching GmbH (ITG) and Nordic Nanovector ASA (OSE: NANO) have signed long-term global supply agreements for the medical radioisotope no-carrier-added Lutetium-177 (n.c.a. 177 Lu) EndolucinBeta ® to support R&D, clinical and commercial supply of Betalutin ® ( 177 Lu-Lilotomab-Satetraxetan).

Under the terms of the agreement for the study phase, ITM has partnered with Nordic Nanovector to support its clinical development. At the same time, both parties signed a commercial agreement for the supply of EndolucinBeta ® post Marketing Approval of Betalutin ®. Additional terms of the agreement are not disclosed.

---------------------------------------------

Bruce Power joined forces with Isotopen Technologien München (ITM) to examine the production of the radioisotope Lutetium-177 at the Bruce Power site, Toronto
Lu-177 is used in targeted radionuclide therapy to treat cancers like neuroendocrine tumours and prostate cancer. The medical-grade radioisotope is used to destroy cancer cells while leaving healthy cells unaffected. According to the company, the Bruce Power site has the ability to meet global supply needs through 2064, which is the lifespan of the station after refurbishment.